Munyo-Estefan Andrés, López-Paullier Matías, Charlone-Granucci Rogelio, Peña-Rehbein Juan L, d'Albora-Rivas Ricardo, Schiavo-Viviani Luis
Departamento de Otorrinolaringología, Hospital de Clínicas, Montevideo, Uruguay.
Acta Otorrinolaringol Esp. 2009 Jul-Aug;60(4):268-71. doi: 10.1016/j.otorri.2009.01.004. Epub 2009 Jun 24.
The aim of this study is to determine whether the incidence of hypothyroidism in patients with Head and Neck Cancer who have undergone neck radiotherapy justifies the inclusion of thyroid function monitoring in the pre-operative and follow-up evaluation protocols.
A retrospective study was conducted with all the patients seen in the Oncology Section of the Otorhinolaryngology Department in the "Hospital de Clínicas", Montevideo, Uruguay, from January 1970 to May 2008. A total of 550 case records were analyzed. Of the 550 patients, 188 were excluded due to the fact they had not received radiotherapy as part of their treatment and 362 were included in the study. Of these, 55 patients had thyroid stimulating hormone (TSH) level determination after treatment with radiation therapy. Hypothyroidism was defined as a TSH value greater than or equal to 4.5 mIU/L, regardless of whether or not any symptoms were presented.
36.4% of the patients were diagnosed as having clinical or sub-clinical hypothyroidism. The type of treatment carried out, particularly whether or not surgical resection was performed, was found to be the most significant predictive factor for the development of hypothyroidism (P=0.054).
Monitoring of the thyroid function on a six-month or annual basis, at least during the first 5 post-treatment years, has to be included in the follow-up and control protocols of every patient undergoing neck RT, and patients with TSH values over 4.5 mIU/L should be referred to the endocrinologist for hormone replacement, whether they present symptoms or not.
本研究的目的是确定接受颈部放疗的头颈癌患者甲状腺功能减退的发生率是否足以证明在术前和随访评估方案中纳入甲状腺功能监测的合理性。
对1970年1月至2008年5月在乌拉圭蒙得维的亚“Clinicas医院”耳鼻喉科肿瘤科就诊的所有患者进行了一项回顾性研究。共分析了550份病例记录。在这550名患者中,188名因未接受放疗作为其治疗的一部分而被排除,362名被纳入研究。其中,55名患者在接受放射治疗后测定了促甲状腺激素(TSH)水平。甲状腺功能减退被定义为TSH值大于或等于4.5 mIU/L,无论是否出现任何症状。
36.4%的患者被诊断为临床或亚临床甲状腺功能减退。所进行的治疗类型,特别是是否进行了手术切除,被发现是甲状腺功能减退发生的最显著预测因素(P=0.054)。
在每位接受颈部放疗的患者的随访和控制方案中,至少在治疗后的前5年,必须包括每6个月或每年监测一次甲状腺功能,TSH值超过4.5 mIU/L的患者,无论是否有症状,都应转诊给内分泌科医生进行激素替代治疗。